MP13-Resistencias a Antiretrovirales
Medicina de precisión / IBS-MP13
The group coordinates the Spanish HIV Research Network Work Package on subtypes and resistance and contributes with several European organizations on HIV resistance (ESAR-SPREAD, Eurocord-CHAIN, EuRESIST-INTEGRATE) and hepatitis resistance (SHARED, HEPCARE). The group has been actively involved in recent research on Transmitted Drug Resistance in Spain and Europe, on genotypic investigation on HIV viral Tropism, on clinical significance of HIV low and very low-level viraemia, and on molecualr epidemiology of HIV ti guide public helath interventions. The group is actively involved in hepatitis C virus research activities, coordianting several activities in GEHEP (Spanish Viral Hepatitis Study Group of the Clinical Microbiology & Infectious diseases Spanish Society), and coordinator of HEPCRESP, the Spanish national cohort on HCV resistance to new DAAs. The group is also in the Sterring Comittee of HEPCARE (Europe) and SHARED (Global) hepatitis
Líneas de investigación
- Eliminación de hepatitis C
- Epidemiología molecular de VIH
- Microbiota e inmunomodulación
- Microbiota y enfermedad
- Microbiota y probióticos
- Resistencias a Antirretrovirales
- Resistencias en VHC
Palabras clave
VIH, Hepatitis C, Microbiota.
Mª DOLORES MERIDA DEL CAÑO
ALEJANDRO PEÑA MONJE
JOSE ANTONIO SANCHEZ ALVAREZ
MARTA ALVAREZ ESTEVEZ
ANTONIO BARRIENTOS DURAN
NATALIA CHUECA PORCUNA
ADOLFO DE SALAZAR GONZALEZ
ANA FUENTES LOPEZ
FEDERICO GARCIA GARCIA
FERNANDO GARCIA GARCIA
CARLOS GERRERO BELTRAN
JOSEFA LOPEZ BUENO
Rescue Therapy for Genotype-3 DAA Non-responders, Almost all Done
ANNALS OF HEPATOLOGY, 2019;
FI:1,895; Q4
The efficiency of several one-step testing strategies for the diagnosis of hepatitis C
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2019;
FI:1,858; Q4
Association of breast and gut microbiota dysbiosis and the risk of breast cancer: a case-control clinical study
BMC CANCER, 2019;
FI:2,933; Q3
Mitral valve repair in infective endocarditis is not inferior to valve replacement: results from a Spanish nationwide prospective registry
GENERAL THORACIC AND CARDIOVASCULAR SURGERY, 2019;
FI:1,219; Q3
A pilot study on the implementation of reflex testing for the diagnosis of active hepatitis C virus infection at two healthcare centres
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2019;
FI:1,685; Q4
Phaeohyphomycosis due to Pleurostomophora richardsiae: an uncommon cutaneous fungal infection
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018;
FI:4,287; Q1
Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe
BMC INFECTIOUS DISEASES, 2018;
FI:2,62; Q2
Modulation of faecal metagenome in Crohn’s disease: Role of microRNAs as biomarkers
WORLD JOURNAL OF GASTROENTEROLOGY, 2018;
FI:3,3; Q2
A safe an easy method for building consensus HIV sequences from 454 massively parallel sequencing data
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2018;
FI:1,707; Q3
Spatiotemporal Characteristics of the HIV-1 CRF02_AG/CRF63_02A1 Epidemic in Russia and Central Asia
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018;
FI:1,935; Q3
Hepatitis C virus core antigen in the management of patients treated with new direct-acting antivirals
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2017;
FI:2,401; Q3
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration
EBIOMEDICINE, 2017;
One-year calorie restriction impacts gut microbial composition but not its metabolic performance in obese adolescents
ENVIRONMENTAL MICROBIOLOGY, 2017;
FI:5,395; Q1
Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing
AIDS REVIEWS, 2017;
FI:3,244; Q2
News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference
AIDS REVIEWS, 2017;
FI:3,244; Q2
Antibacterial activity of isolated phenolic compounds from cranberry (Vaccinium macrocarpon) against Escherichia coli
FOOD & FUNCTION, 2016;
FI:2,686; Q1
Usefulness of Integrase resistance testing in proviral HIV-1 DNA in patients with Raltegravir prior failure
BMC INFECTIOUS DISEASES, 2016;
FI:2,69; Q2
Clinical, epidemiological and treatment failure data among HIV-1 non-B-infected patients in the Spanish AIDS Research Network Cohort
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2016;
FI:1,53; Q3
Phylodynamic and Phylogeographic Profiles of Subtype B HIV-1 Epidemics in South Spain
PLOS ONE, 2016;
FI:3,057; Q1
Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms
PLOS ONE, 2016;
FI:3,057; Q1
News on HIV-HCV Coinfection: Update From the 2015 GEHEP Conference
AIDS REVIEWS, 2015;
FI:3,787; Q2
Genetic Barrier to Resistance for Dolutegravir
AIDS REVIEWS, 2015;
FI:3,787; Q2
In vitro efficacy of daptomycin and teicoplanin combined with ethanol, clarithromycin or gentamicin as catheter lock solutions
BMC MICROBIOLOGY, 2015;
FI:2,729; Q2
Pyrosequencing Analysis Reveals Changes in Intestinal Microbiota of Healthy Adults Who Received a Daily Dose of Immunomodulatory Probiotic Strains
NUTRIENTS, 2015;
FI:3,27; Q2
In vitro sensitivity to ceftaroline of Staphylococcus aureus
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2015;
FI:2,172; Q3
Relevancia Clínica E Impacto Económico de la Correcta Asignación del Genotipo/subtipo del Virus de la Hepatitis C en la Era de Los Antivirales de Acción Directa.
Financiador: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
Número de expediente: PI-0411-2014
Tiempo de ejecución: 31/07/2015 - 30/09/2017
IP: MARTA ALVAREZ ESTEVEZ
Caracterización virológica de los pacientes que no consiguen Respuesta Viral Sostenida a tratamiento con antivirales de acción directa frente al virus de la hepatitis C en regímenes libres de interferón.
Financiador: SOCIEDAD ESPAÑOLA DE ENFERMEDADES INFECCIOSAS Y MICROBIOLOGÍA CLÍNICA
Número de expediente: GEHEP-004-FGG
Tiempo de ejecución: 04/07/2017 - 03/07/2018
IP: FEDERICO GARCIA GARCIA
Caracterización virológica de los pacientes que no consiguen Respuesta Viral Sostenida a tratamiento con Antivirales de acción Directa frente al Virus de la Hepatitis C
Financiador: INSTITUTO DE SALUD CARLOS III
Número de expediente: PI15/00713
Tiempo de ejecución: 01/01/2016 - 31/12/2018
IP: FEDERICO GARCIA GARCIA
Implantación de Una Aplicación Web para la Monitorización y Caracterización A Tiempo Real de Los Clusters Con Alta Tasa de Transmisión del Vih en Andalucía Oriental
Financiador: CONSEJERÍA DE SALUD
Número de expediente: PI-0550-2017
Tiempo de ejecución: 01/01/2018 - 31/12/2020
IP: MARTA ALVAREZ ESTEVEZ
RD16/0025/0040 – RED SIDA- FEDERICO GARCÍA GARCÍA
Financiador: INSTITUTO DE SALUD CARLOS III
Número de expediente: RD16/0025/0040
Tiempo de ejecución: 01/01/2017 - 31/12/2021
IP: FEDERICO GARCIA GARCIA
VIGILANCIA EPIDEMIOLOGICA DE LAS RESISTENCIAS PRIMARIAS Y TRASMITIDAS A LOS ANTIRETROVIRALES EN ESPAÑA. ESTUDIO FILOGENÉTICO, FILODINAMICO Y FILOETNICO
Financiador: INSTITUTO DE SALUD CARLOS III
Número de expediente: PI18/00819
Tiempo de ejecución: 01/01/2019 - 31/12/2021
IP: FEDERICO GARCIA GARCIA